Literature DB >> 22532585

Survival analysis and prognostic nomogram for patients undergoing resection of extrahepatic cholangiocarcinoma.

N A van der Gaag1, J J Kloek, J K de Bakker, B Musters, R B Geskus, O R C Busch, A Bosma, D J Gouma, T M van Gulik.   

Abstract

BACKGROUND: Tumor location of extrahepatic cholangiocarcinoma (CCA) might influence survival after resection.
METHODS: A consecutive series of 175 patients who had undergone a potentially curative resection of extrahepatic CCA was analyzed. We calculated concordance indices of different constructed prognostic models for survival including TNM (tumour-node-metastasis) staging and developed a nomogram of the most sensitive model.
RESULTS: Overall cancer-specific survival rates were 83%, 58%, and 26% at 1, 2, and 5 years, respectively. Cancer-specific survival according to location was 42% for proximal, 23% for mid, and 19% for distal CCA after 5 years. Tumor location was not an independent significant predictor (P = 0.06). A prognostic model using all potential prognostic variables predicted survival better compared with TNM staging (concordance index 0.65 versus 0.63). A reduced model containing only lymph node status, microscopically residual tumor status, and tumor differentiation grade, also outperformed TNM staging (concordance index 0.66).
CONCLUSIONS: Tumor location of extrahepatic CCA does not independently predict cancer-specific survival after resection. We developed a nomogram, based on a prognostic model with lymph node status, microscopically residual tumor status of resection margins, and tumor differentiation grade, that predicted survival better than TNM staging.

Entities:  

Mesh:

Year:  2012        PMID: 22532585     DOI: 10.1093/annonc/mds077

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  29 in total

1.  The Glasgow Prognostic Score accurately predicts survival in patients with biliary tract cancer not indicated for surgical resection.

Authors:  Akira Iwaku; Akiyoshi Kinoshita; Hiroshi Onoda; Nao Fushiya; Hirokazu Nishino; Masato Matsushima; Hisao Tajiri
Journal:  Med Oncol       Date:  2013-12-06       Impact factor: 3.064

2.  Pancreaticoduodenectomy for distal cholangiocarcinoma: surgical results, prognostic factors, and long-term follow-up.

Authors:  Stefano Andrianello; Salvatore Paiella; Valentina Allegrini; Marco Ramera; Alessandra Pulvirenti; Giuseppe Malleo; Roberto Salvia; Claudio Bassi
Journal:  Langenbecks Arch Surg       Date:  2015-07-02       Impact factor: 3.445

3.  Use of preoperative controlling nutritional status (CONUT) score as a better prognostic marker for distal cholangiocarcinoma after pancreatoduodenectomy.

Authors:  Fumihiro Terasaki; Teiichi Sugiura; Yukiyasu Okamura; Takaaki Ito; Yusuke Yamamoto; Ryo Ashida; Katsuhisa Ohgi; Katsuhiko Uesaka
Journal:  Surg Today       Date:  2020-08-06       Impact factor: 2.549

4.  Passive Versus Active Intra-Abdominal Drainage Following Pancreaticoduodenectomy: A Retrospective Study Using The American College of Surgeons NSQIP Database.

Authors:  Madeline Lemke; Lily Park; Fady K Balaa; Guillaume Martel; Jad Abou Khalil; Kimberly A Bertens
Journal:  World J Surg       Date:  2020-10-19       Impact factor: 3.352

5.  Perioperative blood transfusion is not associated with overall survival or time to recurrence after resection of perihilar cholangiocarcinoma.

Authors:  Annemiek M Dekker; Jimme K Wiggers; Robert J Coelen; Rowan F van Golen; Marc G H Besselink; Olivier R C Busch; Joanne Verheij; Markus W Hollmann; Thomas M van Gulik
Journal:  HPB (Oxford)       Date:  2016-01-06       Impact factor: 3.647

6.  Survival after resection of perihilar cholangiocarcinoma-development and external validation of a prognostic nomogram.

Authors:  B Groot Koerkamp; J K Wiggers; M Gonen; A Doussot; P J Allen; M G H Besselink; L H Blumgart; O R C Busch; M I D'Angelica; R P DeMatteo; D J Gouma; T P Kingham; T M van Gulik; W R Jarnagin
Journal:  Ann Oncol       Date:  2015-06-30       Impact factor: 32.976

7.  Expression and prognostic value of glutamate dehydrogenase in extrahepatic cholangiocarcinoma patients.

Authors:  Zheng Su; Gaojie Liu; Tingfeng Fang; Ketao Zhang; Shanglin Yang; Huayao Zhang; Yang Wang; Zejian Lv; Jianping Liu
Journal:  Am J Transl Res       Date:  2017-05-15       Impact factor: 4.060

8.  Improved Survival in Surgically Resected Distal Cholangiocarcinoma Treated with Adjuvant Therapy: a Propensity Score Matched Analysis.

Authors:  Caitlin Hester; Ibrahim Nassour; Beverley Adams-Huet; Mathew Augustine; Michael A Choti; Rebecca M Minter; John C Mansour; Patricio M Polanco; Matthew R Porembka; Sam C Wang; Adam C Yopp
Journal:  J Gastrointest Surg       Date:  2018-07-20       Impact factor: 3.452

9.  Transcriptome analysis reveals dysregulated long non-coding RNAs and mRNAs associated with extrahepatic cholangiocarcinoma progression.

Authors:  Fumin Zhang; Ming Wan; Yi Xu; Zhenglong Li; Pengcheng Kang; Xingming Jiang; Yimin Wang; Zhidong Wang; Xiangyu Zhong; Chunlong Li; Yunfu Cui
Journal:  Oncol Lett       Date:  2017-09-18       Impact factor: 2.967

10.  Neoadjuvant chemoradiotherapy followed by liver transplantation for unresectable cholangiocarcinoma: a single-centre national experience.

Authors:  Sophie Duignan; Donal Maguire; Chamarajanagar S Ravichand; Justin Geoghegan; Emir Hoti; David Fennelly; John Armstrong; Kathy Rock; Helen Mohan; Oscar Traynor
Journal:  HPB (Oxford)       Date:  2013-04-18       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.